Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Adocia SA is a French clinical-stage biotechnology company headquartered in Lyon, specializing in the discovery and development of innovative therapeutic solutions for chronic metabolic diseases, particularly diabetes and obesity. Founded in 2005 by the Soula family, it focuses on enhancing treatments through proprietary technology platforms including BioChaperone®, AdoShell®, AdOral®, and AdoXLong, which enable advanced formulations of approved proteins and peptides such as ultra-rapid insulin lispro, co-formulations like BioChaperone Combo (insulin glargine and lispro), and preclinical innovations like AdoShell Islets for cell therapy and oral semaglutide. Adocia's diversified pipeline spans Phase 1 to Phase 3 clinical trials, addressing unmet needs in type 1 and type 2 diabetes management and obesity therapies. The company employs around 75-79 people and follows a business model of licensing proprietary products and platforms to pharmaceutical partners after proof-of-concept, exemplified by alliances like Tonghua Dongbao for Asian markets. With a strong patent portfolio in insulin therapy, chronic wound healing, and monoclonal antibodies, Adocia plays a pivotal role in advancing hormonal and cell-based treatments within the biotechnology sector.
€4.15
€0.07 (-1.66%)
EOD Aug 14, 2026
The business is unprofitable at the operating level (-1068.68% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 84.2% YoY. Margins deteriorated 989.3pp alongside, both lines moving the wrong way.
ROIC dropped from -46.93% to -112.08%, capital efficiency is deteriorating. Negative free cash flow of -€7M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€1M
▼ -84.2% YoY
Net Income (TTM)
-€17M
▼ -78.0% YoY
Op. Margin
-1068.68%
▼ -989.3pp YoY
ROIC
-112.08%
▼ -65.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€7M
▲ +57.1% YoY
Op. Cash Flow (TTM)
-€7M
▲ +58.3% YoY
Net Debt
-€8M
Net Cash Position
Cash & Equiv.
€17M
3Y CAGR: -49.5%
Continue Research
Adocia SA (ADOC.XPAR)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Adocia SA scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Adocia SA scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -1,068.7% operating margin and a -112.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ADOC.XPAR's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.